Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
16.37
+0.03 (0.18%)
May 22, 2026, 4:00 PM EDT - Market closed
Theravance Biopharma Revenue
Theravance Biopharma had revenue of $17.70M in the quarter ending March 31, 2026, with 15.02% growth. This brings the company's revenue in the last twelve months to $109.78M, up 68.20% year-over-year. In the year 2025, Theravance Biopharma had annual revenue of $107.46M with 66.92% growth.
Revenue (ttm)
$109.78M
Revenue Growth
+68.20%
P/S Ratio
7.69
Revenue / Employee
$1,219,722
Employees
90
Market Cap
843.92M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 107.46M | 43.08M | 66.92% |
| Dec 31, 2024 | 64.38M | 6.96M | 12.12% |
| Dec 31, 2023 | 57.42M | 6.08M | 11.84% |
| Dec 31, 2022 | 51.35M | -3.97M | -7.17% |
| Dec 31, 2021 | 55.31M | -16.55M | -23.03% |
| Dec 31, 2020 | 71.86M | -1.56M | -2.12% |
| Dec 31, 2019 | 73.41M | 13.04M | 21.61% |
| Dec 31, 2018 | 60.37M | 44.98M | 292.37% |
| Dec 31, 2017 | 15.39M | -33.26M | -68.37% |
| Dec 31, 2016 | 48.65M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Geron | 196.12M |
| Arbutus Biopharma | 191.45M |
| Xencor | 97.36M |
| MeiraGTx Holdings | 79.76M |
| Evommune | 10.00M |
| Omeros | 9.89M |
| Odyssey Therapeutics | 2.98M |
TBPH News
- 15 days ago - Theravance Biopharma reports Q1 EPS (10c) vs. (17c) last year - TheFly
- 16 days ago - Theravance Biopharma Earnings release: Q1 2026 - Filings
- 16 days ago - Theravance Biopharma Quarterly report: Q1 2026 - Filings
- 16 days ago - Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update - PRNewsWire
- 25 days ago - Theravance Biopharma Proxy statement: Proxy filing - Filings
- 6 weeks ago - Theravance Biopharma price target raised to $17 from $14 at B. Riley - TheFly
- 2 months ago - Theravance Biopharma price target raised to $15 from $13 at TD Cowen - TheFly
- 2 months ago - Theravance Biopharma reports Q4 EPS $1.15, consensus $1.10 - TheFly